GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » EV-to-FCF

LAVA Therapeutics NV (LAVA Therapeutics NV) EV-to-FCF : 0.33 (As of Apr. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, LAVA Therapeutics NV's Enterprise Value is $-13.02 Mil. LAVA Therapeutics NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.70 Mil. Therefore, LAVA Therapeutics NV's EV-to-FCF for today is 0.33.

The historical rank and industry rank for LAVA Therapeutics NV's EV-to-FCF or its related term are showing as below:

LVTX' s EV-to-FCF Range Over the Past 10 Years
Min: -31.44   Med: -0.07   Max: 68.66
Current: 0.44

During the past 5 years, the highest EV-to-FCF of LAVA Therapeutics NV was 68.66. The lowest was -31.44. And the median was -0.07.

LVTX's EV-to-FCF is ranked better than
78.01% of 391 companies
in the Biotechnology industry
Industry Median: 4.47 vs LVTX: 0.44

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), LAVA Therapeutics NV's stock price is $2.85. LAVA Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.570. Therefore, LAVA Therapeutics NV's PE Ratio for today is At Loss.


LAVA Therapeutics NV EV-to-FCF Historical Data

The historical data trend for LAVA Therapeutics NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV EV-to-FCF Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -0.46 -10.24 1.20

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.24 -29.09 53.53 -10.15 1.20

Competitive Comparison of LAVA Therapeutics NV's EV-to-FCF

For the Biotechnology subindustry, LAVA Therapeutics NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LAVA Therapeutics NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's EV-to-FCF falls into.



LAVA Therapeutics NV EV-to-FCF Calculation

LAVA Therapeutics NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-13.020/-39.702
=0.33

LAVA Therapeutics NV's current Enterprise Value is $-13.02 Mil.
LAVA Therapeutics NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LAVA Therapeutics NV  (NAS:LVTX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

LAVA Therapeutics NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.85/-1.570
=At Loss

LAVA Therapeutics NV's share price for today is $2.85.
LAVA Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


LAVA Therapeutics NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.